基本信息
浏览量:0
职业迁徙
个人简介
Interests:
The ability to precisely control where drugs accumulate in the body after systemic administration would be transformative for treating a wide array of diseases from cancer to autoimmunity to organ rejection. Molecularly targeted nanomedicines (e.g. antibody-coated nanoparticles) were initially developed in the hope of realizing this anatomic precision to thereby significantly enhance efficacy and reduce toxicity. Unfortunately, multiple unsuccessful clinical trials have confirmed that we do not yet understand how to translate robust targeting in a petri dish into an effective therapeutic for a person. The two most significant impediments facing targeted nanomedicine are: 1) a lack of model systems with direct relevance to humans and 2) the lack of a theoretical framework to define the molecular properties necessary for therapeutically-relevant targeting. The recently developed clinical technique of Ex Vivo Normothermic Machine Perfusion (NMP), a method used to resuscitate and assess marginal organs during transplantation, provides a unique opportunity to overcome both these obstacles and thereby engineer a new generation of precision nanomedicines with direct translatability to man.
The central motivation of the Tietjen lab is to pioneer a synergistic bridge between nanotechnology and clinical organ transplant. More specifically, we aim to work directly with transplant clinicians to adapt ex vivo NMP in isolated organs for use as a model system to engineer vascular-targeted nanomedicines. Our work will emphasize the use of non-transplanted human organs to take advantage of the unique ability of NMP to provide a platform for preclinical, quantitative studies performed in viable human tissues. To maximize the experimental impact of each individual organ, we will develop a suite of integrated biophysical tools capable of real-time, 3D characterization of isolated organs undergoing NMP. The ultimate goal of the Tietjen lab is to use the NMP model to simultaneously develop new therapeutic/diagnostic paradigms for use in organ transplant, as well as to establish the theoretical foundation required for anatomic and cellular precision following systemic administration of targeted nanomedicines.
The ability to precisely control where drugs accumulate in the body after systemic administration would be transformative for treating a wide array of diseases from cancer to autoimmunity to organ rejection. Molecularly targeted nanomedicines (e.g. antibody-coated nanoparticles) were initially developed in the hope of realizing this anatomic precision to thereby significantly enhance efficacy and reduce toxicity. Unfortunately, multiple unsuccessful clinical trials have confirmed that we do not yet understand how to translate robust targeting in a petri dish into an effective therapeutic for a person. The two most significant impediments facing targeted nanomedicine are: 1) a lack of model systems with direct relevance to humans and 2) the lack of a theoretical framework to define the molecular properties necessary for therapeutically-relevant targeting. The recently developed clinical technique of Ex Vivo Normothermic Machine Perfusion (NMP), a method used to resuscitate and assess marginal organs during transplantation, provides a unique opportunity to overcome both these obstacles and thereby engineer a new generation of precision nanomedicines with direct translatability to man.
The central motivation of the Tietjen lab is to pioneer a synergistic bridge between nanotechnology and clinical organ transplant. More specifically, we aim to work directly with transplant clinicians to adapt ex vivo NMP in isolated organs for use as a model system to engineer vascular-targeted nanomedicines. Our work will emphasize the use of non-transplanted human organs to take advantage of the unique ability of NMP to provide a platform for preclinical, quantitative studies performed in viable human tissues. To maximize the experimental impact of each individual organ, we will develop a suite of integrated biophysical tools capable of real-time, 3D characterization of isolated organs undergoing NMP. The ultimate goal of the Tietjen lab is to use the NMP model to simultaneously develop new therapeutic/diagnostic paradigms for use in organ transplant, as well as to establish the theoretical foundation required for anatomic and cellular precision following systemic administration of targeted nanomedicines.
研究兴趣
论文共 40 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
C Albert,L Bracaglia, A Koide,J DiRito,T Lysyy,L Harkins, C Edwards, O Richfield,J Grundler, K Zhou, E Denbaum, G Ketavarapu,
Nature communicationsno. 1 (2022): 5998-5998
David Andrijevic,Zvonimir Vrselja,Taras Lysyy,Shupei Zhang,Mario Skarica,Ana Spajic,David Dellal, Stephanie L. Thorn, Robert B. Duckrow,Shaojie Ma,Phan Q. Duy,Atagun U. Isiktas,
John T Langford,Jenna R DiRito,Natty Doilicho, Graylen R Chickering, David A Stern,Xinshou Ouyang,Wajahat Mehal,Gregory T Tietjen
biorxiv(2022)
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn